Drug intelligence / Profile preview

Qurelac

Development stage: Unknown
Lead developer: Mediforum
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Qurelac is a synbiotic dietary supplement developed and marketed by Mediforum. It features a patented blend of 12 probiotic strains (including *Lactobacillus plantarum*, *Lactobacillus rhamnosus*, *Lactobacillus casei*, *Lactobacillus salivarius*, *Lactobacillus fermentum*, *Lactobacillus acidophilus*, *Lactococcus lactis*, *Streptococcus thermophilus*, *Bifidobacterium breve*, *Bifidobacterium bifidum*, *Bifidobacterium longum*, and *Bifidobacterium lactis*) combined with prebiotics, including Japanese patented heat-treated *Lactobacillus* EC-12. Qurelac is designed to improve weakened immune systems, boost intestinal gut flora, support weight loss, and promote bone health. It is administered orally and is commercially available directly to consumers.

Brand names: Qurelac

Beyond the preview

Go deeper on Qurelac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qurelac.

Explore the full profile